Literature DB >> 1798748

The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative.

B A Allison1, E Waterfield, A M Richter, J G Levy.   

Abstract

The influence of lipoprotein association on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative (BPD) has been investigated in M-1 tumor bearing mice. The association of benzoporphyrin mono acid ring A with either low or high density lipoprotein increased tumor cell killing in an in vivo/in vitro cytotoxicity assay performed 3 h post intravenous drug administration. Eight hours following photosensitizer injection only low density lipoprotein (LDL) mixtures produced significant (P less than or equal to 0.005) increases in tumor cell killing compared to BPD in unfractionated plasma. The efficacy of in vivo photosensitization in the presence of lipoproteins correlated with the in vivo/in vitro cytotoxicity. Association of BPD with low or high density lipoproteins resulted in delayed tumor regrowth and higher cure rates when light exposure (125J/cm2) was performed 3 h post drug administration. When light exposure was performed 8 h post-injection only LDL-BPD mixtures led to enhanced tumor eradication compared to BPD administered in aqueous solution or unfractionated plasma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1798748     DOI: 10.1111/j.1751-1097.1991.tb02079.x

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  10 in total

1.  Ascorbate enhances the toxicity of the photodynamic action of Verteporfin in HL-60 cells.

Authors:  Galina G Kramarenko; Werner W Wilke; Disha Dayal; Garry R Buettner; Freya Q Schafer
Journal:  Free Radic Biol Med       Date:  2006-01-19       Impact factor: 7.376

2.  Binding of temoporfin to the lipoprotein fractions of human serum.

Authors:  A T Michael-Titus; R Whelpton; Z Yaqub
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

3.  [Photodynamic therapy with verteporfin for uveal melanoma].

Authors:  J Wachtlin; N E Bechrakis; M H Foerster
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

4.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008

Review 5.  Photodynamic therapy.

Authors:  T J Dougherty; C J Gomer; B W Henderson; G Jori; D Kessel; M Korbelik; J Moan; Q Peng
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

Review 6.  Lipoprotein-inspired nanoparticles for cancer theranostics.

Authors:  Kenneth K Ng; Jonathan F Lovell; Gang Zheng
Journal:  Acc Chem Res       Date:  2011-05-10       Impact factor: 22.384

7.  Tumour-localising and -photosensitising properties of a novel zinc(II) octadecylphthalocyanine.

Authors:  C Ometto; C Fabris; C Milanesi; G Jori; M J Cook; D A Russell
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

8.  Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD).

Authors:  V H Fingar; P K Kik; P S Haydon; P B Cerrito; M Tseng; E Abang; T J Wieman
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma.

Authors:  A Busetti; M Soncin; G Jori; M A Rodgers
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

10.  Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative.

Authors:  B A Allison; P H Pritchard; J G Levy
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.